NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Gracell Biotechnologies (Shanghai) Co., Ltd.
Alexion Pharmaceuticals, Inc.
GlaxoSmithKline
Kedrion S.p.A.